368 related articles for article (PubMed ID: 25956562)
1. [Anti-VEGF therapy in the treatment of anterior segment neovascularization secondary to central retinal vein occlusion].
Kabesha TB; Glacet-Bernard A; Rostaqui O; Souied EH
J Fr Ophtalmol; 2015 May; 38(5):414-20. PubMed ID: 25956562
[TBL] [Abstract][Full Text] [Related]
2. [Results of trabeculectomy with anti-VGEF therapy in the treatment of neovascular glaucoma secondary to retinal vein occlusion (report of 21 cases followed at Bukavu Eye Clinic from January 1 to December 31th, 2015)].
Kabesha TB; Kabesha D; Maloba V; Mwamba C; Chenge B; Mukalay A
J Fr Ophtalmol; 2017 Jan; 40(1):17-21. PubMed ID: 27884546
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.
Wakabayashi T; Oshima Y; Sakaguchi H; Ikuno Y; Miki A; Gomi F; Otori Y; Kamei M; Kusaka S; Tano Y
Ophthalmology; 2008 Sep; 115(9):1571-80, 1580.e1-3. PubMed ID: 18440643
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab as adjuvant for neovascular glaucoma.
Beutel J; Peters S; Lüke M; Aisenbrey S; Szurman P; Spitzer MS; Yoeruek E; ; Grisanti S
Acta Ophthalmol; 2010 Feb; 88(1):103-9. PubMed ID: 18811641
[TBL] [Abstract][Full Text] [Related]
5. Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma--results from a prospective interventional case series.
Lüke J; Nassar K; Lüke M; Grisanti S
Graefes Arch Clin Exp Ophthalmol; 2013 Oct; 251(10):2403-13. PubMed ID: 23893090
[TBL] [Abstract][Full Text] [Related]
6. Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial.
Brown DM; Wykoff CC; Wong TP; Mariani AF; Croft DE; Schuetzle KL;
Retina; 2014 Sep; 34(9):1728-35. PubMed ID: 24914476
[TBL] [Abstract][Full Text] [Related]
7. Early treatment of severe cystoid macular edema in central retinal vein occlusion with posterior sub-tenon triamcinolone acetonide.
Lin JM; Chiu YT; Hung PT; Tsai YY
Retina; 2007 Feb; 27(2):180-9. PubMed ID: 17290200
[TBL] [Abstract][Full Text] [Related]
8. Ocular neovascularization associated with central and hemicentral retinal vein occlusion.
Hayreh SS; Zimmerman MB
Retina; 2012 Sep; 32(8):1553-65. PubMed ID: 22495331
[TBL] [Abstract][Full Text] [Related]
9. [Profile of neovascular glaucoma in Senegalese patients].
Ndiaye-Sow MN; Seck SM; Dieng M; Diakhaté-Diouf M; Agboton GA; Gueye NN
J Fr Ophtalmol; 2018 Sep; 41(7):637-641. PubMed ID: 30166236
[TBL] [Abstract][Full Text] [Related]
10. Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term.
Sun Y; Liang Y; Zhou P; Wu H; Hou X; Ren Z; Li X; Zhao M
BMC Ophthalmol; 2016 Aug; 16(1):150. PubMed ID: 27576739
[TBL] [Abstract][Full Text] [Related]
11. Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma.
Batioğlu F; Astam N; Ozmert E
Int Ophthalmol; 2008 Feb; 28(1):59-61. PubMed ID: 17609852
[TBL] [Abstract][Full Text] [Related]
12. A review of neovascular glaucoma. Etiopathogenesis and treatment.
Dumbrăveanu L; Cușnir V; Bobescu D
Rom J Ophthalmol; 2021; 65(4):315-329. PubMed ID: 35087972
[TBL] [Abstract][Full Text] [Related]
13. Verteporfin photodynamic therapy for anterior segment neovascularization secondary to ischaemic central retinal vein occlusion.
Parodi MB; Iacono P; Ravalico G
Clin Exp Ophthalmol; 2008 Apr; 36(3):232-7. PubMed ID: 18412591
[TBL] [Abstract][Full Text] [Related]
14. Panretinal photocoagulation and photodynamic therapy for anterior segment neovascularization secondary to ischemic central retinal vein occlusion.
Parodi MB; Friberg TR; Pedio M; Fiotti N; Di Stefano G; Ravalico G
Ophthalmic Surg Lasers Imaging; 2007; 38(2):94-9. PubMed ID: 17396687
[TBL] [Abstract][Full Text] [Related]
15. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
16. Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab.
Saito Y; Higashide T; Takeda H; Murotani E; Ohkubo S; Sugiyama K
Am J Ophthalmol; 2010 Jun; 149(6):964-972.e1. PubMed ID: 20381786
[TBL] [Abstract][Full Text] [Related]
17. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma.
Ehlers JP; Spirn MJ; Lam A; Sivalingam A; Samuel MA; Tasman W
Retina; 2008 May; 28(5):696-702. PubMed ID: 18463512
[TBL] [Abstract][Full Text] [Related]
18. Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma.
Higashide T; Murotani E; Saito Y; Ohkubo S; Sugiyama K
Graefes Arch Clin Exp Ophthalmol; 2012 Apr; 250(4):603-10. PubMed ID: 22116499
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma.
Iliev ME; Domig D; Wolf-Schnurrbursch U; Wolf S; Sarra GM
Am J Ophthalmol; 2006 Dec; 142(6):1054-6. PubMed ID: 17157590
[TBL] [Abstract][Full Text] [Related]
20. Neovascular Glaucoma from Ocular Ischemic Syndrome Treated with Serial Monthly Intravitreal Bevacizumab and Panretinal Photocoagulation: A Case Report.
Asif H; Si Z; Quan S; Amin P; Dao D; Shaw L; Skondra D; Qiu M
Case Rep Ophthalmol Med; 2022; 2022():4959522. PubMed ID: 35935916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
